drugset / Trial / NCT07783659
Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC
Phase 1
Not yet recruiting
24 enrolled
M.D. Anderson Cancer Center
Cancer Prevention Research Institute of Texas · collabSJP Biotec · collab
NaSingle-groupOpen-labelTreatment
Summary
To find the optimal (best) recommended dose of zotatifin and carboplatin to treat patients with metastatic or recurrent TNBC.
Timeline
- Start
- 2027-02-12
- Primary completion
- 2030-06-30
- Completion
- 2032-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Zotatifin | Small molecule | — | Intravenous |